GlobeNewswire

Painter 2019: Industry's Most Powerful Digital Paint Software Evolves for Today's Professional Artists

Dela

Latest version offers an all-around more enjoyable user experience thanks to a collection of visual enhancements, performance upgrades, and new brushes that fuel efficiency & creativity

OTTAWA, June 26, 2018 (GLOBE NEWSWIRE) -- Introducing Painter® 2019 - the newest version of the industry's most powerful and creative digital painting software. Designed for professional and aspiring artists on Windows and Mac, Painter 2019 delivers an all-around more enjoyable user experience with a range of enhancements, including stunning visual improvements and modern UI; significant speed and performance boosts; and a collection of all-new brushes to inspire greatness.

"Knowing our users live in Painter every day, we've modernized its look and feel to make the experience of creating art more fluid, streamlined, and enjoyable," said Chris Pierce, Product Manager for Digital Arts at Corel. "These elegant updates make all the difference not only in terms of overall comfort but also to the efficiency of your workflow. If you're a professional artist and your time is money, Painter 2019 is an absolute must-have."

With new and enhanced features, Painter 2019 is the definitive software for artists working in illustration, fine art, gaming, entertainment, comics, manga, photography, and everything in between:

  • NEW! Modern UI for Today's Artists: Painter 2019 introduces a refreshed and professional interface that truly makes your artwork the focus. Main UI elements have been meticulously transformed to reveal an all-new dark theme that allows the interface to melt away so the artwork takes center stage. Continually evolving, Painter now features more than 650 fully redesigned icons that are simple to understand, more efficient to use, and easier on the eyes for artists with high DPI displays.

  • ENHANCED! Performance & Speed Upgrades: Work faster thanks to a number of performance-based enhancements to improve both the brushing experience and working with documents. Artists with AVX2-compatible systems will enjoy up to 38% faster document rendering when zooming, panning, and rotating; as well as brushes that can be up to 75% faster; and an enhanced Brush Ghost that offers a seamless stroke experience with zero lag.
     
  • NEW! Brush Category & More Brushes: Gain inspiration for fresh creations with 36 remarkable new brushes. Discover the all-new Stamps brush category along with a host of additional brushes that round out popular categories such as Selections, Airbrushes, Blenders, Dab Stencils, Glazing, Real Watercolor, Real Wet Oil, Sargent, and Thick Paint. Paint with five new Patterns that are custom designed for concept artists and video game designers, while offering new creative options any artist will love. 

  • NEW & ENHANCED! Color Workflows: Enjoy a more intuitive way to choose and interact with colors using redesigned grabbers in the Color Wheel, Hue Ring, and Saturation/Value Triangle. Users who frequently switch colors can now pin the redesigned Temporal Colors Selector for easy access to any color selection, while greatly reducing the amount of UI in their workspace. And for anyone looking to quickly and easily identify colors that work together, they can now drag the updated color selector over any area of their artwork and instantly discover a color that complements the rest of their masterpiece. 

  • ENHANCED! Multi-Touch, Stylus & Mouse Control: Experience an intuitive way to simultaneously pan, zoom, and smoothly rotate your canvas using two fingers on a Windows touch device, then instantly reset your painting with a simple double-tap. Artists can also quickly zoom in and out of any document with the new Click + Drag feature when using a stylus or mouse. Just click and move to the right to zoom in, or move to the left to zoom out. To zoom into a specific area of interest, just hold the Shift key and drag-click.

Pricing & Availability

Painter 2019 is available in English, French, German, Japanese, and Traditional Chinese for $429 USD / €424.95 / £359.99. Registered owners of any previous version can purchase for the upgrade price of $229 USD / €218.95 / £179.99. UK and European prices include VAT.

Get the free 30-day trial or purchase electronic download versions at www.painterartist.com.

Join the Conversation

Connect with Painter users on Facebook at www.facebook.com/corelpainter, keep up with @CorelPainter on Twitter, discover incredible community artwork on Instagram @CorelPainter, and learn new techniques on the Corel Discovery Center at http://learn.corel.com.

About Corel Digital Arts

Corel is the proud creator of Painter, the world's most realistic paint program. The Painter product family also includes Painter Essentials(TM), the complete entry-level digital art studio, and ParticleShop(TM), a Particle(TM) brush plugin for Photoshop.

Corel is one of the world's top software companies. Our mission is simple: to help people achieve new levels of creativity, productivity, and success.

For more information about the Painter product portfolio, please visit www.painterartist.com.

© 2018 Corel Corporation. All rights reserved. Corel, the Corel logo, the Corel Balloon logo, Painter, Essentials, ParticleShop, and Particle are trademarks or registered trademarks of Corel Corporation and/or its subsidiaries in Canada, the U.S. and elsewhere. All other trademarks mentioned herein are the property of their respective owners. Patents:  www.corel.com/patent .

Alex Brazeau 
PR Manager 
alex.brazeau@corel.com

Photos accompanying this announcement are available at

http://www.globenewswire.com/NewsRoom/AttachmentNg/56b4622e-f62c-4763-8821-8c6f79cc4400

http://www.globenewswire.com/NewsRoom/AttachmentNg/85ed2f1d-6e41-4887-b94d-a77ba3e334d8

http://www.globenewswire.com/NewsRoom/AttachmentNg/df3dcdd2-3bd9-4d46-901f-56170f036176

http://www.globenewswire.com/NewsRoom/AttachmentNg/b4a74aa9-ee9b-488e-ac8f-133871029087




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Corel via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum